Key Drivers
- High gross margin
- Large cash burn
- Reliance on funding
AIAI Summary
SPRY has shifted from a binary clinical gamble to a commercialization-first company with meaningful first‑year U.S. neffy revenue and attractive product gross margins, making valuation hinge on execution of payer access, refill durability, and rapid SG&A/CAC improvement to hit cash‑flow breakeven. If management can demonstrably improve gross‑to‑net and cut CAC or show sustained refill retention, the stock re-rates positively; if payer friction, ~50% net retention, or high SG&A persist, expect dilution and multiple compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Large cash burn
- •Reliance on funding
Spry has strong unit economics and near-term liquidity but is losing substantial cash due to outsized SG&A and heavy free‑cash‑flow burn, forcing reliance on external funding and leaving valuation rich for a loss-making company.
Price Behavior
Key Price Behavior Insights:
- •Below last-month average
- •Near-term support
- •Resistance ~10–15% up
SPRY is trading below its last-month average (~$8.84) at $8.17, showing a short-term downtrend but sitting on a near-term support band around $8.17–$8.90 with resistance near $9.17–$9.30 that must be cleared for a reversal.
Steady decline from ~ $9.30 to $8.17 since early
Sentiment & News
Key News Insights:
- •neffy first-year sales
- •heavy SG&A
- •$245M cash
ARS Pharmaceuticals posted in-line Q4 results with $72.2M in first-year neffy U.S. sales but faces a slow launch, heavy SG&A and a large 2025 loss despite $245M cash, ongoing clinical progress and notable institutional buying.
Mixed commercial traction and strong cash give upside if launches and Phase 2b readout accelerate, but near-term valuation is constrained by burn and slow revenue ramp
Similar Companies in Healthcare
Other companies in the same sector with AI ratings